Suppr超能文献

长链非编码 RNA SNHG16 在人类癌症中的表达的临床病理意义和预后:一项荟萃分析。

Clinicopathological significance and prognosis of long noncoding RNA SNHG16 expression in human cancers: a meta-analysis.

机构信息

Medical Center for Digestive Diseases, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, 210011, China.

出版信息

BMC Cancer. 2020 Jul 16;20(1):662. doi: 10.1186/s12885-020-07149-w.

Abstract

BACKGROUND

Recent studies have highlighted the important role of long non-coding RNA SNHG16 in various human cancers. Here, we conducted a meta-analysis to investigate the effect of SNHG16 expression on clinicopathological features and prognosis in patients with different kinds of human cancers.

METHODS

We performed a systematic search in electronic databases including PubMed, EMBASE, Cochrane Library and Web of Science, to investigate the potential association between SNHG16 expression and prognostic significance and clinical features in cancer patients. Odds ratios (ORs) or hazards ratios (HRs) with corresponding 95% confidence intervals (95% CIs) were pooled to estimate the prognosis value of SNHG16 by StataSE 15.0 software.

RESULTS

A total of 16 eligible studies with 1299 patients were enrolled in our meta-analysis. The results revealed that increased expression level of SNHG16 was significantly associated with larger tumor size (OR: 3.357; 95% CI: 2.173-5.185; P < 0.001), advanced TNM stage (OR: 2.930; 95% CI: 1.522-5.640; P = 0.001) and poor histological grade (OR: 3.943; 95% CI: 1.955-7.952; P < 0.001), but not correlated with smoking status (P = 0.489), sex (P = 0.932), distant metastasis (P = 0.052), or lymph node metastasis (P = 0.155). Moreover, the pooled HR showed that elevated expression SNHG16 was associated with a significantly poorer overall survival (OS) (HR = 1.866, 95% CI: 1.571-2.216, P < 0.001). For the set of cancer types, high expression of SNHG16 was significantly associated with shorter OS in patients with cancers of the urinary system (HR: 2.523, 95% CI:1.540-4.133; P <0.001), digestive system (HR: 2.406, 95% CI:1.556-3.721; P <0.001), and other cancers (including glioma and non-small cell lung cancer) (HR: 1.786, 95% CI:1.406-2.267; P <0.001).

CONCLUSIONS

LncRNA SNHG16 overexpression might serve as an unfavorable prognostic factor, which provides a basis for medical workers to evaluate the prognosis of patients and to help the decision-making process.

摘要

背景

最近的研究强调了长非编码 RNA SNHG16 在各种人类癌症中的重要作用。在这里,我们进行了一项荟萃分析,以研究 SNHG16 表达对不同类型人类癌症患者的临床病理特征和预后的影响。

方法

我们在电子数据库中进行了系统搜索,包括 PubMed、EMBASE、Cochrane 图书馆和 Web of Science,以研究 SNHG16 表达与癌症患者的预后意义和临床特征之间的潜在关联。StataSE 15.0 软件用于汇总比值比(ORs)或风险比(HRs)及其相应的 95%置信区间(95%CI),以估计 SNHG16 的预后价值。

结果

我们的荟萃分析共纳入了 16 项符合条件的研究,共 1299 名患者。结果表明,SNHG16 的表达水平升高与肿瘤较大(OR:3.357;95%CI:2.173-5.185;P<0.001)、TNM 分期较晚(OR:2.930;95%CI:1.522-5.640;P=0.001)和组织学分级较差(OR:3.943;95%CI:1.955-7.952;P<0.001)显著相关,但与吸烟状态(P=0.489)、性别(P=0.932)、远处转移(P=0.052)或淋巴结转移(P=0.155)无关。此外,合并 HR 显示,SNHG16 表达升高与总生存率(OS)显著降低相关(HR=1.866,95%CI:1.571-2.216,P<0.001)。对于癌症类型,SNHG16 的高表达与泌尿系统(HR:2.523,95%CI:1.540-4.133;P<0.001)、消化系统(HR:2.406,95%CI:1.556-3.721;P<0.001)和其他癌症(包括脑胶质瘤和非小细胞肺癌)(HR:1.786,95%CI:1.406-2.267;P<0.001)患者的较短 OS 显著相关。

结论

lncRNA SNHG16 的过表达可能是一个不利的预后因素,为医务人员评估患者的预后并帮助决策过程提供了依据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e2e/7366298/2880780276a6/12885_2020_7149_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验